U.S. markets close in 3 hours 48 minutes
  • S&P 500

    3,861.80
    +19.86 (+0.52%)
     
  • Dow 30

    31,971.07
    +474.77 (+1.51%)
     
  • Nasdaq

    12,820.90
    -99.24 (-0.77%)
     
  • Russell 2000

    2,218.92
    +26.71 (+1.22%)
     
  • Crude Oil

    65.17
    -0.92 (-1.39%)
     
  • Gold

    1,676.30
    -22.20 (-1.31%)
     
  • Silver

    25.17
    -0.11 (-0.44%)
     
  • EUR/USD

    1.1853
    -0.0072 (-0.60%)
     
  • 10-Yr Bond

    1.5980
    +0.0440 (+2.83%)
     
  • GBP/USD

    1.3816
    -0.0012 (-0.09%)
     
  • USD/JPY

    108.9170
    +0.5350 (+0.49%)
     
  • BTC-USD

    50,780.44
    +7.04 (+0.01%)
     
  • CMC Crypto 200

    1,026.42
    +2.21 (+0.22%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

KalVista Pharmaceuticals (KALV) Catches Eye: Stock Jumps 7.4%

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

KalVista Pharmaceuticals, Inc. KALV was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $17.53 – $19.47 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen no estimate revision in the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

KalVista Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

KalVista Pharmaceuticals, Inc. Price

KalVista Pharmaceuticals, Inc. Price
KalVista Pharmaceuticals, Inc. Price

KalVista Pharmaceuticals, Inc. price | KalVista Pharmaceuticals, Inc. Quote

A better-ranked stock in the Medical sector is IDEXX Laboratories, Inc. IDXX, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report
 
KalVista Pharmaceuticals, Inc. (KALV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research